(lp0
S"Why Amicus Therapeutics, Inc. Jumped Higher Today Motley Fool - Mar 1, 2017 Amicus Therapeutics  ended the day up 17%, after the company's CEO John Crowley and his daughter Megan  were highlighted during President Donald Trump's address to Congress last night.The Unlikely Story Of How Amicus Therapeutics Came To Be - BenzingaAmicus Therapeutics, Inc.  Could Be The Force That Brings Change ... - Market Exclusive"
p1
aS'Tronox Ltd  Reaches $17.20 After 6.00% Up Move, Amicus Therapeutics, Inc ... Herald KS - 10 hours ago The stock of Amicus Therapeutics, Inc.  has Outperform rating given on Monday, October 5 by Leerink Swann.Still A Value Trap?  Amicus Therapeutics, Inc. , SunPower Corporation ... - USA Commerce DailyAmicus Therapeutics, Inc.  Reaches $7.20 After 7.00% Up Move, Inogen ... - MoneyMakingArticles'
p2
aS"Today's Research Reports on Biotech Stocks to Watch: Amicus Therapeutics and ... Yahoo Finance - Mar 17, 2017 Amicus has had a number of investment firms, including JP Morgan Chase, confirming or raising their rating of the company from a &quot;hold&quot; to a &quot;buy&quot; during the early months of 2017, with consensus rating as &quot;outperform&quot;. The company specializes in the&nbsp;..."
p3
aS'Amicus Therapeutics Inc.  Soars 7.89% on February 27 Equities.com - Feb 27, 2017 Amicus Therapeutics Inc.  had a good day on the market for Monday February 27 as shares jumped 7.89% to close at $6.43.'
p4
aS'Amicus Therapeutics Launches Galafold  for Treatment of Fabry ... GlobeNewswire  - Feb 27, 2017 CRANBURY, N.J., Feb. 27, 2017  -- Amicus Therapeutics , a global biotechnology company at the forefront of rare and orphan diseases, has commenced the commercial launch of the precision medicine Galafold in the&nbsp;...Amicus Therapeutics  Launches Galafold in the UK - StreetInsider.com'
p5
aS'Amicus Therapeutics Announces Full-Year 2016 Financial Results and Corporate ... GlobeNewswire  - Mar 1, 2017 CRANBURY, N.J., March 01, 2017  -- Amicus Therapeutics , a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced financial results for the full year ended December 31,&nbsp;...Amicus Therapeutics, Inc.  Receives Prestigious SOTU Attention - StockNewsUnion'
p6
aS'Stock Value Analysis: Amicus Therapeutics, Inc.  The Oracle Examiner - 15 hours ago While predicting the next move of Amicus Therapeutics, Inc. , volatility is an important factor to look at. Currently Amicus Therapeutics, Inc.  has weekly volatility of 4.84%% and monthly volatility of 5.77%%. In the words of investopedia ...'
p7
aS'Amicus Therapeutics Inc.  Moves Higher on Volume Spike for March 03 Equities.com - Mar 3, 2017 Amicus Therapeutics Inc.  traded on unusually high volume on Mar. 03, as the stock gained 4.85% to close at $7.79. On the day, Amicus Therapeutics Inc. saw 5.65 million shares trade hands on 24,755 trades. Considering that the stock averages only&nbsp;...AMICUS THERAPEUTICS,INC.  Files An 8-K Other Events - Market ExclusiveAmicus Therapeutics, Inc.  recently sold by insider Campbell Bradley L - Post Analyst'
p8
aS'Amicus Therapeutics Inc.: Amicus Therapeutics to Announce Full-Year 2016 ... The Wall Street Transcript - Feb 22, 2017 CRANBURY, N.J., Feb. 22, 2017  -- Amicus Therapeutics , a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced a conference call and live audio webcast on&nbsp;...Earnings Guidance on Amicus Therapeutics, Inc. - Energy IndexAmicus Therapeutics, Inc. : How technical signals have emerged? - Post Analyst'
p9
aS"Analyst's Indicator Review for AGNC Investment Corp. , Amicus ... The USA Commerce - Mar 17, 2017 Latest closing price was 3.15% above its 50-day moving average and 6.34% above its 200-day moving average. On 03/16/2017 close, Amicus Therapeutics, Inc.  plummeted -0.97% to $7.12. The stock currently has a Market Cap of $1.01B.Amicus Therapeutics, Inc.  Upgraded by Zacks Investment Research to Hold - Chaffey BreezeAmicus Therapeutics, Inc.  loses confidence of 27 hedge fund managers - Post Analyst"
p10
a.